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Abstract
Tauopathy is a category of neurodegenerative diseases that are caused or associated with 
pathological tau protein. Some of the diseases are relatively common, which include 
Alzheimer’s disease (AD) and various Parkinsonism (PD). Tau protein is a type of micro-
tubule-associated protein (MAP), encoded by the gene MAPT (microtubule-associated 
protein tau). Normally, tau binds to microtubule, supporting the assembling and struc-
ture of cytoskeletons. However, in tauopathy, normal tau protein undergoes abnormal 
posttranslational modifications and detaches from microtubule; furthermore, they may 
aggregate forming paired helical filaments (PHF) or straight filaments (SF). Abundant 
PHF could be observed under microscope as fibrillary tangles. In this chapter, we will 
introduce the pathogenesis process of tauopathy with regard to the posttranslational 
modifications of the protein, the animal models, and the developing treatments against 
tauopathy from a clinical prospective.
Keywords: tau, phosphorylation, truncation, kinases, Alzheimer’s diseases,  
clinical trials
1. Introduction
Tauopathy is used to summarize all the diseases that the pathogenesis processes are related to 
tau protein. Tau is one of the most common proteins involved in neurodegenerative diseases. In 
many tauopathy cases, tau protein seeds and forms intracellular fibrillary tangles on itself, one 
of the pathological hallmarks of Alzheimer diseases [1]. The tangles formations are believed 
mostly due to altered posttranslational modifications of tau protein, which detaches from 
microtubules and binds each other forming aggregates. In several parkinsonism-associated 
movement disorders, including frontotemporal dementia with parkinsonism-17 (FTDP-17), 
progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), mutations in tau 
have been identified, and those altered tau are prone to tangles formation [2]. The  common 
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involvement of tau protein in a range of neurological disorders makes it one of the most stud-
ied proteins. However, despite it has been studied for approximately 30 years since tau is 
coined as the major component of fibrillary tangles, concrete evidence that detail tauopathy in 
molecular and cellular levels is still limited [3], and most of the pathological data are obtained 
from studies using postmortem brain. Therefore, how tau protein and its dynamic changes 
affect the pathogenesis of various neurodegenerative diseases is still a mystery. Many out-
standing questions are being stressed, including which posttranslational modifications are 
critical for it to gain toxicity, does other neurodegenerative diseases involved proteins interact 
with tau protein, which brain regions or cell types are most susceptive to the toxicity of tau 
and how the aggregates cause cellular dysfunction, and which forms of tau during the tangle 
formation process are toxic. In this process, some widely accepted concepts are being chal-
lenged. For example, traditionally, it is believed that hyperphosphorylation of tau induces it 
to detach from microtubule and increases its toxicity, but recent findings suggest some phos-
phorylations are protective instead [4, 5]. These findings will be emphasized in the following 
sections. Apparently, more efforts are needed before we can reach a definitive answer for these 
questions. Some exciting technological advances promise further exploration of some exist 
questions and more unexplored fields involving tau protein.
2. Tau biology and pathology
Tau pathology, namely fibrillary tangles, was observed way before the protein was identified. 
In fact, it was Alois Alzheimer who first described the heavy burdens of this never reported 
feature in his demented patient back to 1906 [6]. Seventy years later, tau protein was isolated 
as a factor that is critical for the re-polymerization of some depolymerized tubulins to form 
microtubules in vitro [7]. After another 10 years, a series studies confirmed that the tangles 
observed in AD brain are composed of tau [3, 8–10]. Since then, tau received significant atten-
tion in AD research. Nevertheless, as researchers soon realized tau pathology in a panel of 
neurological dysfunction, solving the underlying mechanism of tauopathy has been regarded 
as a unique field of neurobiology.
2.1. Tau biology
2.1.1. Tau’s interaction with microtubule
The expression of tau protein varies in different tissues, but the brain has the most abun-
dant level. In brains, tau is predominately expressed in neurons but can also be detected 
in glial cells, especially in oligodendrocytes [11]. In neurons, tau proteins are mainly local-
ized in axons, but they are not excluded from dendrites [12]. Functional analyses in vitro 
demonstrated that tau plays critical roles in both microtubules assembly and maintaining the 
structural stabilization [7, 13]. But not until recently, researchers are starting to understand 
the interactions between tau and microtubule in real-time by adopting different newly devel-
oped techniques. By fusing a Halo-tag, a dehalogenase modified to bind certain fluorescent 
ligand; tau could be labeled and monitored in live imaging [14]. With tubulins being labeled 
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with photoactivatable green fluorescent protein (PAGFP), the interactions between tau and 
tubulins are viewed under total internal reflection fluorescence microscope (TIRF). With such 
high resolution and relatively short time frame, the live imaging revealed that tau moves 
on microtubule quickly without direction. In authors’ words, it could “hops on and off” to 
another microtubule in milliseconds and moves along a microtubule with little dwindle time 
[14, 15]. In another study, under transmission electron microscope (TEM), it was found that 
tau could promote the microtubule assemble by laterally crosslinking protofilaments [13]. 
Moreover, tau showed a preference to bind GDP-tubulin over GTP-tubulin, but the reason 
behind it is not understood [13].
2.1.2. Tau structures and functions
Tau is encoded by the gene MAPT (microtubule-associated protein tau), which is located on 
chromosome 17q21. MAPT has 15 exons, and the alternative splicing of the mRNA resulted 
in six different isoforms. The longest one among these has 441 amino acids, which is often 
referred as full-length tau. In late 1980s, the basic protein structure of tau was defined [16, 17], 
and it was realized that the C-terminus of tau protein contains repeated domains responsible 
for the binding of microtubules [17]. The basic structure and functions of each functional 
region of it are summarized as follow:
On the N terminal side (1–150), it has two N-terminal domains. Each has 29 amino acids, one 
from 45 to 74 and another from 75 to 103. The physiological functions of N terminal domain 
are largely unknown, and speculations on that including it could play roles in signal trans-
duction as tau could co-immunoprecipitated with phospholipase C gamma through the bind-
ing sites within N terminus [18].
The N terminal side is followed by two proline-rich domains, one from 151 to 198 followed by 
another from 199 to 243. Studies showed that this region interacts with src kinase family mem-
bers, such as fyn serving for signal transductions [19, 20]. Furthermore, it was shown that tau 
could interact with beta and gamma actins, which are the subtypes of actins commonly seen 
in neurons [21]. A panel of different truncated and or mutated tau was generated to test the 
interactions of it with actins, and it was found that the proline-rich regions were responsible 
for this interaction [21].
The proline-rich region is followed by microtubule binding region (244–370), which is com-
posed of four repeated domains and each one of them contains 18 highly conserved amino 
acids. The microtubule binding region directly binds to tubulin, which plays the most critical 
role in microtubule interaction [22]. Because the N terminal side does not bind to microtubule 
and was thought to interact with other proteins, the N terminal side plus the first proline-rich 
domain is often referred as projection domain of tau. The rest residues, including the second 
proline-rich domain and microtubule binding domains as well as the C terminal tail, are often 
referred as microtubule assembly domain [23].
Because the full-length tau has all these N terminal regions (2 N) and C terminal repeats 
(4R), it is also referred as “2N4R” tau. The rest of other tau isoforms found in brain are the 
combinations of either lacks one (the second N terminal domain; 1 N) or two N terminal 
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domains (0 N) or does not contain the second microtubule-binding domain (3R). Therefore, 
isoforms “1N4R”, “0N4R”, “2N3R”, “1N3R,” and “0N3R” are simply denoting the major 
functional domains of tau [22, 23]. The dominate forms found in human brain are 2N4R 
and 2N3R. Under physiological conditions, the ratio of isoforms with 4R and 3R is around 1 
[24]. While in pathological conditions, the expression of tau isoforms could favor one form, 
especially 2N4R for most tauopathies. Researchers have long noticed the ratio alterations 
in disease conditions, but the exact meaning and the reason behind this change are still 
unknown [25].
Under physiological condition, tau exists in an unfolded state, and 80% of the proteins inter-
act with microtubule in neurons [22, 26]. When tau is not interacting with other proteins, it 
may curl on its own, and this random curled state is believed important for preventing inter-
actions with other tau proteins by masking the possible interacting sites [27, 28]. The protein 
itself is bipolar; the N-terminal side is highly negatively charged in normal physiology, while 
the proline-rich domain and C-terminal end are positively charged, allowing it to interact 
with the negatively charged C-terminal of tubulins [22, 29]. Various posttranslational modi-
fications could alter its charge. Paired helical filaments (PHFs) are relatively acidic compared 
to normal full-length tau, which is believed due to the phosphorylation of the amino acid 
residues [30, 31]. Tau is also very hydrophilic, containing only a small portion of hydrophobic 
residues [27]. Both the net charge changes and a possible shift from being hydrophilic to 
hydrophobic are speculated of contributing to its aggregation behavior under pathological 
conditions [28, 31]. Also, normal tau proteins only exhibit transient secondary structures [27]. 
Phosphorylation of certain residues may prompt tau to form secondary structures, which is 
revealed by pseudophosphorylation of all the residues that could be recognized by phospho-
tau specific antibodies AT8, AT100, and PHF1 and are shown by the structural changes in 
nuclear magnetic resonance spectroscopy [32]. But how normal tau proteins are transformed 
to form aggregates remains a mystery.
Given that tau may exist in various forms and structures, one shall be mindful not to overstate 
the possible role of tau based on data derived from truncated/engineered tau, which may only 
have the N terminal side or the C terminal side [18, 33–35]. Nevertheless, we have gained 
more understanding of tau and its function from previous works, but better manipulations 
are needed before we can be comfortable about applying those bench-side results to tauopa-
thies treatment.
2.2. Tau pathology
Tauopathies feature a variety of pathological brain defects, such as neurites dystrophy, cell 
loss of certain brain regions, and brain shrinkage. The patients show associated symptoms 
like the decline of cognitive function, memory loss, and defects of the visual system. In the 
postmortem brains of most affected patients, tau aggregations are commonly found.
2.2.1. Formation of fibrillar tangles
The fibrillar tangle is the hallmark of tauopathy. The formation process of this aberrant salient 
could generally be categorized into several stages described as follow:
Cognitive Disorders36
Step 1. Conformational change of tau: Certain sites phosphorylation and other posttransla-
tional modifications or genetic mutation of MAPT rendering tau bind to tubulins with 
reduced affinity and detaches from microtubules no longer support the microtubule 
assemble, increasing the free tau protein pool [22, 36].
Step 2. Oligomer formation: The detached tau proteins form globular oligomers, which are 
composed of 40 monomers in vitro in the presence of heparin [37]. The mainstream opin-
ion speculates that the detached/modified tau proteins, especially the hyperphosphory-
lated types, are prone to interact with each other. The phosphorylation on the residues of 
C-terminal and proline-rich domains neutralizes the charges of the region and reduces the 
net charge of the protein by which it may contribute to losing the natively unfolded prop-
erty and prohibit the intramolecular interactions of tau protein [22, 38, 39]. On the other 
hand, it was reported that the two cysteine residues on tau, cysteine-291 and cysteine-322, 
play a pivotal role in the tau dimerization [40] because oxidation of the residues may lead 
to the disulfide bond formation between tau monomers, which potentially seeds for the 
oligomerization process. This theory is supported by the frequent observation of oxida-
tive stress in tauopathies [41]. Moreover, a recent study showed a compound which could 
effectively inhibit heparin-induced tau oligomerization was through its interaction with 
the cysteine residues [37]. However, tau can also form cysteine-independent oligomers 
[40]. Another recent study adopted tau fragment (aa. 297–391), which is the core of PHF, 
to study the role of cysteine in the polymerization of tau in the absence of heparin [42]. 
The results showed that replacement of the cysteine residue or in the presence of reducing 
agents, the polymerization process was accelerated rather than decelerated [42].
It is noteworthy that most of these studies used anionic agents like heparin to induce the 
oligomerization of different recombinant tau isoforms or fragments to test the intrinsic prop-
erties and the effects of the modifications in vitro. But to what extent could this artificially 
induced tau oligomerization reflects the real pathological process is questionable. A recent 
study showed that heparin-induced recombinant tau tangles have little seeding ability in the 
wild-type mouse. In contrast, tau tangles isolated from patients have a strong seeding abil-
ity, and the pathology could spread quickly to different brain regions, shedding lights on 
the difference between in vitro generated tau tangles and in situ harvested tau tangles [43].
Step 3. PHF formation: Tau oligomers may further develop into more complex structures like 
PHF or straight filaments (SF) [44]. It has been shown that in different tauopathies, the ratio 
of PHF/SF and their sizes may vary [45, 46]. For example, in Alzheimer’s disease, PHF is 
more commonly observed than SF [45]. On the other hand, in progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD), and pick’s disease (PiD), SF is predominately 
found [46]. In certain cell types beyond neurons, tau inclusions may exhibit different mor-
phologies and have been given different names to describe their shapes [47]. With the help 
of Cryo-Electron Microscopy (Cryo-EM), we are now able to identify the structures with 
high resolutions [48]. It becomes clear that the cores of the filaments are composed of eight 
β-sheets which requires some hydrophobic interactions between individual peptides; the dif-
ference between PHF and SF is due to the lateral interactions between the sheets. However, 
disulfide bonds formed in the structures remain to be determined [48]. The β-sheets formed 
in tau oligomers and PHF could be detected with thioflavin T or S staining [28].
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2.2.2. Uniqueness of different tauopathies
As mentioned above, tau inclusions are found in different types of cells in different tauop-
athies. In Alzheimer’s disease (AD), tau inclusions are found in neurons as neurofibrillary 
tangles (NFT). While in many other tauopathies, the inclusions are found both in neurons 
and glia cells. Also, the compositions of the inclusions are different. In many tauopathies, the 
inclusions are mainly composed by 4R tau, while in PiD, 3R tau is the dominant form in the 
inclusions. In AD, the ratio of 3R/4R is close to 1 albeit the expression favors 2N4R [46]. How 
the different tau tangles are constructed and what the chemical and physical factors attribut-
ing the assembled pattern are still an enigma. Moreover, the locations where the aggregates 
are first found are also different, following different transmission pathways [46]. Together 
these indicate that although tau aggregate is the hallmark for all tauopathies, the properties 
of the inclusions are different and the factors that trigger various pathological changes may 
also be different [43, 46].
2.2.3. Tau degradation
Normally, the lifetime of tau is short. It was tested in cultured cells that the lifetime of tau is 
within 24 hours [49, 50]. It is presumed that tau proteolysis is mainly controlled by protea-
somes degradation and in vitro studies also support this notion [51]. Since many endogenous 
proteolytic enzymes can cleave tau proteins, it is likely there is some coordination which may 
exist among them and also with the proteasomes [51]. Nevertheless, in tau pathology, the 
turnover time for tau significantly increased. It has been reported that tau phosphorylation 
inhibits the protein degradation [52], which could explain its pathogenic link. Recently, stud-
ies showed autophagy is involved in the digestion of tau, especially for those bulky inclusions 
that are probably hard to be digested by the proteasome [53]. It was found hyperphosphory-
lated tau co-localized with LC3 positive vesicles, a critical autophagy adaptor protein, in post-
mortem brains of different tauopathies [54]. More importantly, many evidence directly shows 
that both proteasome and autophagy systems are impaired in tauopathies, likely resulting 
from the assault of tau aggregation [55, 56].
For proteasome-mediated degradation of tau, different studies have shown that proteasome 
activities are decreased in tauopathies. Both in a tauopathy animal model or AD brains, iso-
lated tau of sarkosyl-insoluble fraction was co-immunoprecipitated with proteasome subunits 
[57, 58]. Furthermore, incubating proteasome with fibrillar tau or tau oligomers decreased the 
activities of the proteasome, whereas when it was incubated with monomer tau, the activities 
were not affected, demonstrating that pathological tau might cause proteasome dysfunction 
[57]. It was observed that the ubiquitinated protein levels are increased in a tauopathy model, 
and PHF tau was also ubiquitinated in both animal models and AD brains [57, 59, 60]. While 
these results demonstrate a nice correlation between proteasome function and tau degrada-
tion, whether the turnover of normal or pathological tau depends on proteasome or not is still 
unclear [61].
For autophagy, it was observed that the dystrophic neuritis of postmortem AD brains con-
tains huge amounts of autophagic-like vacuoles, which are presumably to be autophagosome 
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or autolysosomes. These observations imply a significant upregulation of autophagy activi-
ties preceded by certain stimuli like cytoskeletal dysregulation or oxidative stress, likely caus-
ing the neurons to initiate apoptosis and contribute to neurites dystrophy [55, 56, 62]. Dense 
lysosome proteases staining results in AD brains also indicate defective degradation of major 
intracellular protein aggregates. Moreover, in the familial AD, presenilin 1 mutation is one 
of the most common mutations causing the disease. Traditionally, it is believed the patho-
genic mechanism is that the expression of presenilin 1 mutations results in the generation of 
Amyloid-beta, as this molecule constitutes the active domain of γ-Secretase. However, pre-
senilin 1 also plays a critical role in autophagy that functions as an ER chaperon transport-
ing enzyme subunit critical for lysosome protease activation. Deletion of presenilin 1 could 
abolish autophagy [56]. All these results support the notion that tau aggregation may cause 
upregulation of autophagy activity.
3. Pathogenesis of tauopathy
There are two forms of tauopathy, familial and sporadic. Familial tauopathy is linked with 
genetic mutations of tau, and sporadic tauopathy is often associated with altered posttrans-
lational modifications. Since the pathogenesis of the two forms is different, so they are dis-
cussed separately in the sections below.
3.1. Genetic mutations of tau
3.1.1. Tau mutations in neurodegenerative disorders
Genetic mutations of tau can cause familial tauopathies, which are commonly found in frontal 
temporal dementia (FTD), including a range of clinical conditions like Pick’s disease, cortico-
basal dementia, and progressive supranuclear palsy [63, 64]. Mutations of tau were first dis-
covered in the late 1990s in inherited FTD families [65], and it was the first known monogenic 
mutations that could cause FTD [63, 64]. Epidemiological surveys showed MAPT mutations 
are responsible for 5–20% FTD cases [63]. Since MAPT is localized to chromosome 17 and the 
subject showed FTD with parkinsonism syndrome, it was named frontotemporal dementia 
and parkinsonism linked to chromosome 17 (FTDP-17) to refer tau mutations-associated FTD 
[66]. More than a hundred tau mutations have been identified, and not all of them are patho-
genic. A detailed mutations list and their associated impacts can be found online at Alzforum.
org [67]. Tau mutations are rarely found in Alzheimer’s disease (AD) and normally are not 
considered as a major genetic risk factor for the disease’s familial form. But certain mutations 
could contribute to the pathogenesis of AD, and some found that mutations’ pathogenicity 
has not been integrated yet [67, 68].
3.1.2. Tauopathy animal models
Pathogenic tau mutations typically result in either RNA splicing variation causing the ratio 
change of 3R/4R or a structure change, which will further affect its binding affinity with 
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microtubule and other proteins or promote its self-assembly [66, 67, 69]. The mutation sites 
cover the whole protein and could also be in the introns affecting the RNA splicing [67]. Some 
much more common mutations have been selected in generating transgenic models for study-
ing tauopathies [70]. To date, 28 tauopathy mouse models have been reported according to 
Alzhforum.org and many of which are overexpressing models [67]. Other tauopathy animal 
models in Drosophila, zebrafish, and C. elegans also help the field to untangle the molecular 
and cellular complexity of this clinical condition [71–74].
Transgenic expression of normal human tau in mouse models with either 3R or 4R forms 
were unable to induce significant pathological changes [75]. While with strong pan-neuronal 
promoters could induce more pathological features, this approach also raises a concern of 
overwhelmed tau expression, which may lead to possible artificial effects by causing heavy 
burdens on protein degradation systems, which obviously deviated from the progressive 
pathogenesis that is responsible for the sporadic tauopathy [75–77]. Notably, a recent study 
created transgenic mice expressing an N-terminal truncated tau under the control of human 
tau promoter so to mimic the normal expression level and by which recapitulated some major 
pathological features of tauopathies [76]. The authors claimed that a similarly truncated tau 
could be found in postmortem progressive supranuclear palsy brains, which makes this find-
ing quite interesting.
In comparison, expressing disease-linked mutant tau can induce more pronounced pathologi-
cal effects, and some of the models are widely used in basic or pre-clinical research settings 
if not in combined with other tauopathy-related protein expression [67, 70, 75, 77]. The most 
commonly adopted tau mutations in transgenic animal models are P301L, P301S, R406W, and 
V337 M [59, 77]. All these mutants were found in FTD patients, and their expression showed 
reduced binding affinity to the microtubule. Importantly, all of them could efficiently induce 
tau filaments formations in mouse models, although the composition of the filaments may be 
different for different tau mutations [66, 70]. Among them, three mouse models stand out in 
terms of their wide usage in basic research, as well as in the pre-clinical tests of drug devel-
opment. These are P301L, PS19, and rTg4510 (r for regulatable), all of which were developed 
in the mid-2000s [78–80]. P301L mice overexpress 2N4R tau with P301L mutation under the 
pan-neuronal driver Thy1 [78]. PS19 mice overexpress 1N4R tau with P301S mutation driven 
by mouse prion protein promoter [79], and rTg4510 adopts the tet-off system to overexpress 
0N4R tau bearing P301L mutation only in the absence of tetracycline that controlled by Ca2+/
calmodulin-dependent protein kinase II (CAMKII) promoter [80]. In general, rTg4510 and 
PS19 mice show more massive pathology burdens in comparison with to P301L. Although 
overt tau aggregations were observed in all three types of mice and showed cognitive defects, 
only rTg4510 and PS19 were reported to induce significant neuronal loss [79, 80]. PS19 mice 
showed severe hippocampus shrinkage at the age of 9 months, while rTg4510 mice showed 
gross forebrain atrophy at the age of 10 months [79, 80]. It is noteworthy that human tau 
expression levels were several times higher than the endogenous mouse tau levels for all three 
models [78–80].
These data collectively show that while significant tau aggregates can be induced by expressing 
mutant tau, the models are different from sporadic tauopathy, especially in terms of studying 
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the pathogenesis and treatment methods for tauopathy with a mouse. Another major concern is 
related to the modulation of endogenous enzymes at the time of human tau expression, which 
is an issue difficult to control. Some key features related to general pathogenesis process were 
missed from the transgenic mice models, including robust tau propagation and significant cell 
apoptosis [48, 81]. In one study, by injecting insoluble tau to mouse hippocampus, it was found 
that the seeding and propagation ability of the synthesized insoluble tau are much weaker than 
the insoluble fraction of isolated tau from the AD in vivo [48]. Together, it shows there is still a 
long way to go before using these animal models to find a strategy for detour tauopathy.
Recent advances in human stem cell research may provide a solution for tauopathy and related 
research. By grafting human stem cell-derived neuron to express amyloid-beta in mouse brain, 
a study revealed that the human neurons are more susceptible to the toxicity of amyloid-beta 
than mouse neurons [81]. This observation proved the discrepancy of cells from the two organ-
isms. Therefore, if the quality of the grafted cells and the surrounding microenvironment rep-
resent the physiological conditions in the human brain, shall we also expect human neurons 
are more susceptible to the toxicity of tau?
3.2. Posttranslational modifications of tau
Most patients who suffer from tauopathies carry wild-type MAPT. Therefore, posttransla-
tional modifications of tau are believed to be the key of tau pathogenesis and have been the 
major area of tauopathy research for years. Understanding the posttranslational modifica-
tions of tau not only helps us to pin down the pathogenic mechanism but also offers a viable 
path for drug screen by targeting certain enzymes that modifying tau. As mentioned in the 
above sections, altered posttranslational modifications of tau could render the protein to lose 
its native unfolded structure and by which to promote aggregate formation. In this process, 
the modifications also changed the interactions between tau and other proteins in addition to 
tubulins. So far, 10 types of tau posttranslational modifications have been documented [82], 
among which phosphorylation and truncation are most found, representing the majority of 
the modifications, while other modifications (ubiquitylation, oxidation, glycosylation, glyca-
tion, nitration, acetylation, and sumoylation) are either not often discussed in this setting or 
just recently founded. In total, over 100 sites on a tau protein have been proposed that could 
be modified if not considering the truncation [83].
3.2.1. Phosphorylation
In one of the pioneer studies aimed to prove that neurofibrillary tangles are made of tau, the 
researchers found treating the tissue section with phosphatase could dramatically increase the 
antibody labeling of tau on the tangles [9], and the researchers coined the staining as “atypical 
phosphorylated” tau. Since then, the “hyperphosphorylated” tau under pathological condi-
tions received a great deal of attention. Many protein kinases have been proposed to play 
roles in tau phosphorylation, and some of them have been confirmed by in vivo studies [9, 84]. 
Recent developments have proposed to try out some kinase inhibitors as potential tauopa-
thy therapeutics [85]. For a 2N4R tau protein, it consists of 45 serine residues, 35 threonine 
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residues, 12 histidine residues, and 5 tyrosine residues. Current postulated phosphorylation 
sites have essentially covered most of the available sites, and indeed many of these residues 
are found being phosphorylated under physiological conditions. Therefore, the widespread, 
and likely dynamic, tau phosphorylation appears to serve for certain uncovered functions. 
Nevertheless, it also indicates that the differences in general phosphorylation and changes 
of phosphorylation state in certain residues may play a critical role in tauopathies [83, 84]. 
Moreover, hyperphosphorylated tau could also be detected in other pathological conditions 
aside from tauopathy. It was found that phosphorylated tau proteins are co-aggregated with 
alpha-synuclein in Parkinson disease and Lewy bodies dementia [86]. In some reports, phos-
phorylated tau aggregation can be found in Huntington disease and amyotrophic lateral 
sclerosis brains [87, 88]. In traumatic brain injury patients, the levels of phosphorylated tau, 
but not total tau, are significantly increased [89]. Recently, it is also suspected that tau phos-
phorylation may play a role in type 2 diabetes, rendering the patients incline to have cognitive 
defects [90]. These data collectively indicate hyperphosphorylation of tau has a strong correla-
tion with a variety of brain pathologies, not just tauopathies.
However, the scenario of pathogenesis in tau hyperphosphorylation is more than merely the 
activation of some kinases or down-regulation of some phosphatase. As a matter of fact, dif-
ferent kinases are interacting, regulating, and even competing with each other for acting or 
interfering on same sites [91, 92], it is conceivable that the dynamics of transferring/removing 
phosphate groups on tau protein could be complex. Besides, kinases have multiple substrates, 
and some of them have important roles in normal cell functions [91]. The activities change of a 
kinase could lead to a domino effect toward the change of cellular activities. Last but not least, 
not all phosphorylations are toxic as some of them are required for normal tau functions, 
and certain sites phosphorylation may even serve as a protective effect in tauopathies [4, 5]. 
Therefore, a systemic dissection of disease-prone tau phosphorylations and their regulation is 
a pre-requisite before aiming such complex regulation for a therapeutic exploration.
To study the phosphorylations, many antibodies recognizing specific phosphorylated resi-
dues on tau have been generated, and a list can be found on Alzforum.org [93]. For analyzing 
the effect of phosphorylation, recombinant MAPT constructs bearing site-specific mutations 
to mimic potential phosphorylation status of tau are regularly utilized in tauopathy research, 
which provides some insights regarding the genotoxic and structural impacts upon modifi-
cations [94]. However, even with the recombinant tau with or without pseudo-phosphory-
lations, it is hard to generate significant polymerization in vitro postulated due to a lack of 
“nucleation” process, although pseudo-phosphorylated tau may be prone to aggregate [95].
3.2.1.1. GSK3β
It is well acknowledged that glycogen synthase kinase 3 beta (GSK3β) plays a pivotal role in 
tau hyperphosphorylation [96, 97]. An early study showed that recombinant tau and micro-
tubule-associated GSK3β that were harvested from bacterial lysates could be co-eluted in 
immunochromatography with anti-GSK3β and co-immunoprecipitated [98]. A subsequent 
study found active GSK3β co-localized with tau inclusions in tauopathy brain tissues, and the 
amount of active GSK3β was significantly increased in the patients [99]. Moreover, in vitro 
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study found active GSK3β could efficiently facilitate tau tangles formation after tau are ini-
tially polymerized in the presence of arachidonic acid [100]. It should be noticed that effects 
of GSK3β in tau-mediated toxicity are unsettled; a report found that overexpression of GSK3β 
in tauopathy models may not necessarily lead to shortened lifespan or accelerate pathological 
burden in the animal model [101]. In contrast, results from some studies hinted that activa-
tion of GSK3β is critical for exacerbating tauopathy [102, 103]. These observations should be 
interpreted carefully as the tau models used or compared are not in the same background.
GSK3β is a constitutively active protein that can autophosphorylate its tyrosine residues like 
Tyr 216 to increase the enzyme stability [104]. The activity of GSK3β is mainly regulated 
by insulin and Wnt signaling pathways [105]. When insulin pathway is activated, protein 
kinase B/Akt will be activated, which in turns phosphorylate serine 9 on GSK3β and causes 
its inactivation. In the case of activated Wnt signaling pathway, the inhibition of GSK3β activ-
ity would alleviate the degradation of β-catenin, whose nuclear translocation is responsible 
for the downstream genes activation of the pathway, but the precise mechanism regarding 
tauopathy modulation is still unknown [106, 107]. Nevertheless, a report showed both path-
ways are being downregulated in AD [96].
It was postulated that the phosphorylation by GSK3β requires the priming of adjacent proline 
residue as GSK3β is a member of proline-directed kinase family [84]. So far, more than 40 sites 
in tau, either serine or threonine, have been reported could be phosphorylated by GSK3β, and 
some of them are exclusively found in pathological conditions [84]. Among these sites, in vitro 
study first identified tau could be phosphorylated by GSK3β at the sites S202, S396, and S404 
[108]. Since then, different studies reported many different phosphorylation sites with the 
availability of the corresponded phospho- site-specific antibodies. Some in vitro/in vivo stud-
ies later confirmed that frequent phosphorylation sites include S262, S396, and S404 [101, 109]. 
The phosphorylation of some residues may play important roles in affecting the binding affin-
ity between tau and tubulins or regulating synaptic plasticity [4, 110, 111]. However, it is 
still unknown which residues are most frequently phosphorylated by GSK3β under different 
pathological states in contrast to normal condition, and if there is any protective effect by 
GSK3β phosphorylation against tau from forming the aggregates. Probing these questions 
is a major challenge but will help our understanding of the role of GSK3β in tau-associated 
disease conditions.
3.2.1.2. Other kinases
Besides GSK3β, other kinases such as p38, cyclin-dependent kinase 5 (CDK5), c-Jun N-terminal 
kinase (JNK), extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), dual specificity 
tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), casein kinase (CK), protein kinase 
A (PKA), and Ca2+ /calmodulin-dependent protein kinase II (CAMKII) have been reported to 
involve in directing tau phosphorylation [4, 84, 112–114]. Although the possible phosphory-
lation sites mediated by these kinases, especially in tauopathy conditions, may be less than 
GSK3β, it is fair to say that their roles in modulating tau toxicity are less well studied, thus 
whether the modulations by these kinases are less critical than GSK3β in tauopathy remain to 
be addressed. Indeed, a recent study found P38γ overexpression could  ameliorate  excitotoxicity 
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induced by amyloid-beta in a tau-dependent manner. Further experiments showed that the 
effect was mediated by the phosphorylation of tau S205 through the action of P38γ, and the 
phosphorylation of this residue could abolish the interaction between tau and Fyn and PSD95, 
which otherwise could form a complex interacting with NMDA receptor to induce excitotox-
icity [4]. This result strongly suggests different kinases may have different roles in tauopa-
thy, and not every up-regulated tau phosphorylations under pathological conditions are for 
enhancing the toxicity. Given such complex modifications, more studies shall emphasize the 
difference of activity among these kinases under physiological and pathological conditions, 
as another recent study showed that ERK1/2 does not phosphorylate tau under physiological 
condition [115]. Furthermore, since the pathology development in tauopathy usually takes 
years, whether there is any sequential activation of the kinases appears to be another intriguing 
issue. Indeed, a recent study examining tau-staining in the postmortem AD brains of different 
stages showed that N-terminal side of tau is preferentially phosphorylated at early stages [116].
3.2.2. Truncation
Proteases including calpain and caspases are involved in tauopathy pathogenesis [117, 118]. 
They are activated in tauopathies, either directly cleave tau or indirectly cleaving its associ-
ated kinases, affecting the structure/function of tau [118–121]. While less commonly reported, 
other proteases are suspected to play roles in tauopathy-related protein truncations [122].
Two truncated tau proteins have caught attention in tauopathy, as they are abundant in the 
postmortem AD brains [123]. In fact, truncated tau could also found in other tauopathies 
beyond AD. Importantly, researchers used live multiphoton imaging combined with thio-
flavin S administration and a dye for activated caspases and observed that the tangle forma-
tion was preceded by caspases activation in a classic P301L tauopathy mice (tg4510) [124], 
indicating a close tight between tau cleavage and toxicity. Currently, two truncation sites, 
E391 and D421, have been characterized and both are on the C-terminus. We also learned that 
the truncation on D421 is mediated by caspases, mainly by Caspase-3. D421-truncated tau is 
associated with lysosome in AD brain, indicating that the truncated tau may be favored to be 
degraded through autophagy or maybe impairing the autophagy system [124]. However, it is 
still unclear what kind of proteases are responsible for the cleavage at E391, albeit the site was 
the first-identified cleavage site in tau, and its C-terminal cleavage product appears in PHF 
core [118, 123, 125–128]. While various reports have suggested that caspase and calpain are 
capable of cleaving tau and both present as an early event in pathogenesis and could aggra-
vate tau toxicity [124, 129, 130], an important issue should be solved in studying tau trunca-
tion that is whether the aberrant increase of tau truncation is a consequence of tau aggregation 
or actually the cause that induces tau aggregate formation [124].
3.2.2.1. Calpains
Calpains are cytosolic calcium-dependent cysteine proteases. In an analysis of a postmortem 
brain lysates, calpain 1 was found to activate at early stages of AD, close to the stage when 
GSK-3β and CDK5 were activated [130]. The human genome has two identified calpain  family 
members, calpain 1 and calpain 2. Calpain 1 is mainly expressed by neurons and thus received 
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most attention by researchers concerning neurodegeneration, and calpain 2, on the other 
hand, is mostly expressed by glial cells. Studies have shown that calpain 1 can cleave p35 to 
generate p25, which could further induce prolonged activation of CDK5 [120]. Calpain can 
also cleave GSK3β to generate a C-terminal truncated form, which makes its inhibitory site 
less likely to be phosphorylated and thus produces a dominant-active GSK3β [121, 131]. Also, 
calpain can directly process tau and generate small fragments. However, the physiological or 
pathological impacts of those cleaved calpain products in regarding tauopathy are unclear, 
and the calpain-mediated tau cleavage site(s) remains elusive [120, 127, 132].
3.2.2.2. Caspases
Among the caspases, executive caspases, especially caspase-3, play a critical role in the direct 
processing of tau at the site D421. As mentioned above, D421-truncated tau can be found 
in AD brains, and this cleaved form is suspected to facilitate tau aggregate formation and 
thus enhancing the toxicity [124, 129, 133, 134]. Phosphorylation at S422 could prevent the 
truncation, which could be mediated by JNK and TTBK-1 [114, 135, 136]. Nevertheless, JNK 
and TTBK-1 could also phosphorylate tau at the sites other than S422, which complexes the 
protective scenario [114, 136]. Caspase 3 can also regulate the phosphorylation of tau through 
cleaving and activates protein kinase B and thereby activates GSK3β [119].
Besides caspase-3, other caspases may involve in tauopathy as well. A recent study showed that 
caspase-2 could cleave tau at the site D314. This truncated tau could not participate in tau aggre-
gation but is existing in the brains of P301L mice by a significant amount. Pseudophoshorylation 
of this site prevented caspase-2 cleavage and consequently caused memory and cognitive 
defects of the mice [137].
3.2.3. Acetylation
Tau lysine residues could be acetylated by certain endogenous acetyltransferase, and such 
modulations were first demonstrated by p300 and Creb-binding protein (CBP) [138, 139]. 
Importantly, the insoluble tau protein fraction isolated from postmortem brains of the AD 
patients could be recognized by an anti-acetylated tau antibody [138]. Since then, tau acetyla-
tion studies start to emerge, and up to date, four tau acetylation sites, K174, K274, K280, and 
K281, have been confirmed in pathological conditions [140]. Acetylation of K280 and K281 
reduced tau binding affinity to microtubules in vivo and facilitated tau aggregation in vitro 
[140, 141]. Moreover, acetylation of K280 exacerbated tau toxicity in a Drosophila model, and 
acetylation of K174 worsened neurodegeneration and behavior defects in PS19 mice [142, 143]. 
An overall tau acetylation effect is likely to aggravate tau toxicity. A study showed the admin-
istration of salsalate, a drug that could inhibit p300, ameliorated the tau pathology and mem-
ory defects in PS19 mice [143]. Interestingly, a recent study reported acetylation of K321 could 
impede S324 phosphorylation, a frequent modification in postmortem AD brains. This obser-
vation leads to an intriguing prospect that some switches from acetylation to phosphorylation 
might affect disease progression [144]. Altogether, these studies bring up questions including 
to what extent tau acetylation could affect tau toxicity and whether there are interactions 
between tau acetylation and other posttranslational modifications.
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3.2.4. Other posttranslational modifications
So far, our understanding of other tau modifications is still limited [82]. Take glycosylation 
as an example, glycosylation of tau was only found under pathological conditions but not 
physiological conditions [145], indicating that this type of posttranslational modification has 
a significant impact toward cell function. However, probed glycosylation sites of tau are lim-
ited, and some of the proposed sites might overlap with the known phosphorylation sites, 
suggesting a potential competition between glycosyltransferase and phosphorylation kinases 
[145]. The role of glycosylation in tauopathy is unknown [82]. A recent study using Drosophila 
showed that different gene locus of glycosyltransferases might have a different impact on 
tauopathy [146].
4. Tauopathy treatment
To date, no drug targeting tauopathies has entered the market [147]. Over the past two 
decades, a dozen representative drugs have been pursued in the clinical trials [148], and these 
drugs represented the major therapeutic approaches in tauopathy treatment, including tau 
aggregation inhibitors, tau phosphorylation-related kinase inhibitors, microtubule stabilizers, 
and immunotherapy against tau. However, since these strategies have yet to show signifi-
cant benefit, new approaches are being probed, among which a scheme to enhancing pro-
tein homeostasis is an intriguing approach [147, 149]. Other alternative approaches including 
using traditional Chinese medicine are also being pursued [150].
4.1. Treatment approaches target features of tauopathy
Five treatment approaches mentioned above have been scrutinized in clinical trials, and 
only microtubule stabilization and immunotherapy against tau are still active tau aggrega-
tion inhibitors, and phosphorylation kinase inhibitors, including GSK3β inhibitors and CDK5 
inhibitors, were once favored, but they showed little efficacy in clinical trials [151].
4.1.1. Tau aggregation inhibitors
The direct inhibition of tau aggregation was the major therapeutic strategy being developed 
and had entered the clinical trials [151]. The development of tau aggregation inhibitor was 
initiated in the mid-1990s. The first platform to screen the drugs was reported in 1996 with the 
discovery of phenothiazine, a relatively potent tau aggregation inhibitor in vitro [152]. In this 
platform, recombinant PHF core tau fragment was incubated in wells, by reciprocal treating 
the wells with recombinant full-length tau, the protease-resistant tau aggregation could form 
[152]. By incubating the wells with compounds, the goal was to identify inhibitors that could 
effectively disrupt tau aggregation through the high-throughput assay, and phenothiazine 
showed a strong potency [152]. Unfortunately, phenothiazine was found no efficacy in clinical 
trials, and it was blamed for its poor absorption and was difficult to be transported into the 
brain [153]. Years later, a renewed platform was designed [153]. In this platform, fibroblasts 
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overexpressing a cocktail of different tau isoforms were incubated in wells. This setting could 
yield tau aggregations inside the cells, and compounds were tested to compare the labeled tau 
immunofluorescence as the readout [153]. Although this platform was a lower throughput, 
it overcame the shortages of the first platform in which cytotoxicity was unknown [153, 154]. 
With this platform, TRx0237 was later selected to be the lead candidate and went into clini-
cal trials [151]. Unfortunately, the drug did not work in phase 3 as it failed to slow cognitive 
decline in AD patients [155].
Biochemically, the inhibitors could be categorized into two types, covalently and no-cova-
lently tau aggregation inhibitors [156]. However, although they are called “tau” inhibitors, 
these chemicals are most likely inhibitors to other protein aggregations, and their selectivity is 
highly questionable [151]. Therefore, a highly selective with high-affinity tau inhibitor is still 
waiting to be discovered [151, 156].
4.1.2. Tau immunotherapy
The aim of immunotherapy is to clear pathological tau through the immune system [157]. It 
could be achieved either by applying antibodies that could recognize pathological tau or by 
vaccination to elicit activation of antigen presenting cells and subsequently the B cells and T 
cells to clear up pathological tau [157, 158]. Ten years have passed since the publication of the 
first study on tau immunotherapy [159]. In the study, the researchers showed that inoculation 
of a tau peptide aa R379-L408, which covers two critical phosphorylation sites S396 and S404 
that being phosphorylated in P301L tau mice, could successfully elicit endogenous immune 
system to generate antibodies against tau, and the animal showed ameliorated symptoms of 
tauopathy-related behavior and decreased tau aggregation [160]. Multiple different antibod-
ies or vaccines aiming at different tau epitopes have been developed since then, and some 
have entered the early phases of clinical trials [157].
4.2. Novel treatment approaches
Molecular chaperones play important roles in protein homeostasis. It was reported that inhib-
iting heat shock protein 90 (Hsp90) could inhibit tau toxicity in tauopathy model [160]. The 
mechanism behind could involve Hsp90 stabilize p35, the activator of CDK5, GSK3β, and 
tau, inhibiting their degradation [160, 161]. On the other hand, Hsp70 could facilitate protein 
ubiquitination and degradation by the proteasome [162]. Overexpression of Hsp70 in cells 
could decrease tau aggregation in vitro [163]. Recently, it is also suggested that targeting co-
chaperones of Hsp90 could offer another approach to ameliorate tauopathy [164].
Several traditional Chinese medicines have been suggested that might be useful for treating 
tauopathies [150, 165]. Huannao Yicong Decotion was shown to improve learning and mem-
ory in rat AD model. Immunolabeling showed the expression levels of GSK3β, CDK5, and 
TTBK1 in CA1 region of the hippocampus are downregulated in the drug treatment groups 
[150]. Interestingly, it was also suggested that some traditional Chinese medicines, including 
Huperzine A and Tianma, could induce upregulation of ubiquitin ligases, indicating that they 
might facilitate protein degradation through ubiquitin-proteasome pathway [166].
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
47
5. Conclusion
In this chapter, we discussed major basic aspects of tauopathy, from tau normal functions 
to pathology formation process and from tau genetic mutations to posttranslational modi-
fications. Finally, we discussed currently proposed tauopathy treatment methods. With the 
findings showing tau proteins are involved in many brain pathology conditions beyond 
tauopathy and more evidences showing the roles of tau in Alzheimer’s disease are critical, 
it is expected to receive more basic research attentions in the future [167, 168]. Better animal 
models tailored for different tauopathy are of pursuit, which will benefit both basic research 
and clinical drug developments.
Author details
Hao Chi1, Tzu-Kang Sang1* and Hui-Yun Chang2
*Address all correspondence to: tksang@life.nthu.edu.tw
1 Institute of Biotechnology, National Tsing-Hua University, Hsinchu City, Taiwan
2 Institute of Systems Neuroscience, National Tsing-Hua University, Hsinchu City, Taiwan
References
[1] Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: 
Assessing sex and gender differences. Clinical Epidemiology. 2014;6:37-48. DOI: 10.2147/
CLEP.S37929
[2] Siuda J, Fujioka S, Wszolek Z. Parkinsonian syndrome in familial  frontotemporal demen-
tia. Parkinsonism & Related Disorders. 2014;20(9):957-964. DOI: 10.1016/j.parkreldis. 
2014.06.004
[3] Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major 
antigenic component of paired helical filaments in Alzheimer disease. Proceedings of 
the National Academy of Sciences. 1986;83(11):4044-4048
[4] Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, Przybyla M, 
Bi M, van Hummel A, Stevens CH, Ippati S, Suh LS, Macmillan A, Sutherland G, Kril JJ, 
Silva AP, Mackay J, Poljak A, Delerue F, Ke YD, Ittner LM. Site-specific phosphorylation 
of tau inhibits amyloid-β toxicity in Alzheimer's mice. Science 2016;354(6314):904-908. 
DOI: 10.1126/science.aah6205
[5] Povellato G, Tuxworth RI, Hanger DP, Tear G. Modification of the Drosophila model 
of in vivo tau toxicity reveals protective phosphorylation by GSK3β. Biology Open. 
2014;3(1):1-11. DOI: 10. 1242/bio.20136692
Cognitive Disorders48
[6] Hippius H, Neundörfer G. The discovery of Alzheimer's disease. Dialogues in Clinical 
Neuroscience. 2003;5(1):101-108
[7] Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essen-
tial for microtubule assembly. Proceedings of the National Academy of Sciences. 
1975;72(5):1858-1862
[8] Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer's 
disease: An immunohistochemical study. Journal of Submicroscopic Cytology. 1985; 
17(1):89-96
[9] Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal 
phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskel-
etal pathology. Proceedings of the National Academy of Sciences. 1986;83(13):4913-4917
[10] Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease 
share antigenic determinants with the axonal microtubule-associated protein tau (tau). 
Proceedings of the National Academy of Sciences. 1986;83(11):4040-4043
[11] Martha AK, Kenneth JC. Glial tau pathology in tauopathies: Functional consequences. 
Journal of Experimental Neuroscience. 2015;9(Suppl 2):43-50. DOI: 10.4137/JEN.S25515
[12] Meaghan M, Sumihiro M, Keith V, Lennart M. The many faces of tau. Neuron. 2011; 
70(3):410-426. DOI: 10.1016/j.neuron.2011.04.009
[13] Duan AR, Jonasson EM, Alberico EO, Li C, Scripture JP, Miller RA, Alber MS, Goodson 
HV. Interactions between tau and different conformations of tubulin: Implications for 
tau function and mechanism. Journal of Molecular Biology. 2017;429(9):1424-1438. DOI: 
10.1016/j.jmb
[14] Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, Wood MG, 
Learish R, Ohana RF, Urh M, Simpson D, Mendez J, Zimmerman K, Otto P, Vidugiris G, 
Zhu J, Darzins A, Klaubert DH, Bulleit RF, Wood KV. HaloTag: A novel protein label-
ing technology for cell imaging and protein analysis. ACS Chemical Biology. 2008;3(6): 
373-382. DOI: 10.1021/cb800025k
[15] Janning D, Igaev M, Sündermann F, Brühmann J, Beutel O, Heinisch JJ, Bakota L, Piehler J, 
Junge W, Brandt R. Single-molecule tracking of tau reveals fast kiss-and-hop interac-
tion with microtubules in living neurons. Molecular Biology of the Cell. 2014;25(22): 
3541-3551. DOI: 10.1091/mbc.E14-06-1099
[16] Lee G, Cowan N, Kirschner M. The primary structure and heterogeneity of tau protein 
from mouse brain. Science. 1988;239(4837):285-288
[17] Himmler A, Drechsel D, Kirschner MW, Martin DW Jr. Tau Consists of a set of pro-
teins with repeated C-terminal microtubule-binding domains and variable N-terminal 
domains. Molecular and Cellular Biology. 1989;9(4):1381-1388
[18] Amadoro G, Serafino AL, Barbato C, Ciotti MT, Sacco A, Calissano P, Canu N. Role 
of N-terminal tau domain integrity on the survival of cerebellar granule neurons. Cell 
Death and Differentiation. 2004;11(2):217-230. DOI: 10.1038/sj.cdd.4401314
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
49
[19] Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family 
non-receptor tyrosine kinases. Journal of Cell Science. 1998;111(Pt21):3167-3177
[20] Bhaskar K, Yen SH, Lee G. Disease-related modifications in tau affect the interaction 
between Fyn and tau. The Journal of Biological Chemistry. 2005;280(42):35119-35125. 
DOI: 10.1074/jbc.M505895200
[21] He HJ, Wang XS, Pan R, Wang DL, Liu MN, He RQ. The proline-rich domain of tau 
plays a role in interactions with actin. BMC Cell Biology. 2009;10:81. DOI: 10.1186/1471- 
2121-10-81
[22] Kolarova M, García-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau 
protein in Alzheimer disease. International Journal of Alzheimer's Disease. 2012;2012: 
731526. DOI: 10.1155/2012/731526
[23] Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews. Neuroscience. 
2016;17(1):5-21. DOI: 10.1038/nrn.2015.1
[24] Ginsberg SD, Che S, Counts SE, Mufson EJ. Shift in the ratio of three-repeat tau and four-
repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive 
impairment and Alzheimer's disease. Journal of Neurochemistry. 2006;96(5):1401-1408. 
DOI: 10.1111/j.1471-4159.2005.03641.x
[25] Chen S, Townsend K, Goldberg TE, Davies P, Conejero-Goldberg C. MAPT isoforms: 
Differential transcriptional profiles related to 3R and 4R splice variants. Journal of 
Alzheimer's Disease. 2010;22(4):1313-1329. DOI: 10.3233/JAD-2010-101155
[26] Bakota L, Brandt R. Tau biology and tau-directed therapies for Alzheimer's disease. 
Drugs. 2016;76(3):301-313. DOI: 10.1007/s40265-015-0529-0
[27] Avila J, Jiménez JS, Sayas CL, Bolós M, Zabala JC, Rivas G, Hernández F. Tau Structures. 
Frontiers in Aging Neuroscience. 2016;8:262. DOI: 10.3389/fnagi.2016.00262
[28] Jeganathan S, von Bergen M, Mandelkow EM, Mandelkow E. The natively unfolded char-
acter of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 
2008;47(40):10526-10539. DOI: 10.1021/bi800783d
[29] Mukrasch MD, von Bergen M, Biernat J, Fischer D, Griesinger C, Mandelkow E, 
Zweckstetter M. The “jaws” of the tau-microtubule interaction. The Journal of Biological 
Chemistry 2007;282(16):12230-12239. DOI: 10.1074/jbc.M607159200
[30] Ksiezak-Reding H, Binder LI, Yen SH. Alzheimer disease proteins (A68) share epitopes 
with tau but show distinct biochemical properties. Journal of Neuroscience Research. 
1990;25(3):420-430. DOI: 10.1002/jnr.490250320
[31] Uversky VN. What does it mean to be natively unfolded? European Journal of Bio-
chemistry. 2002;269(1):2-12. DOI: 10.1046/j.0014-2956.2001.02649.x
[32] Bibow S, Ozenne V, Biernat J, Blackledge M, Mandelkow E, Zweckstetter M. Structural 
impact of proline-directed pseudophosphorylation at AT8, AT100, and PHF1 epitopes 
Cognitive Disorders50
on 441-residue tau. Journal of the American Chemical Society. 2011;133(40):15842-15845. 
DOI: 10.1021/ja205836j
[33] Paholikova K, Salingova B, Opattova A, Skrabana R, Majerova P, Zilka N, Kovacech B, 
Zilkova M, Barath P, Novak M. N-terminal truncation of microtubule associated protein 
tau dysregulates its cellular localization. Journal of Alzheimer's Disease. 2015;43(3):915-
926. DOI: 10.3233/JAD-140996
[34] Pooler AM, Hanger DP. Functional implications of the association of tau with the plasma 
membrane. Biochemical Society Transactions. 2010;38(4):1012-1015. DOI: 10.1042/
BST0381012
[35] Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ, Laurent C, Demeyer D, 
Carrier S, Buée-Scherrer V, Blum D, Vinh J, Sergeant N, Verdier Y, Buée L, Hamdane M. 
Role of the tau N-terminal region in microtubule stabilization revealed by new endog-
enous truncated forms. Scientific Reports. 2015;5:9659. DOI: 10.1038/srep09659
[36] Sibille N, Huvent I, Fauquant C, Verdegem D, Amniai L, Leroy A, Wieruszeski JM, 
Lippens G, Landrieu I. Structural characterization by nuclear magnetic resonance of 
the impact of phosphorylation in the proline-rich region of the disordered tau protein. 
Proteins. 2012;80(2):452-462. DOI: 10.1002/prot.23210
[37] Soeda Y, Yoshikawa M, Almeida OF, Sumioka A, Maeda S, Osada H, Kondoh Y, Saito A, 
Miyasaka T, Kimura T, Suzuki M, Koyama H, Yoshiike Y, Sugimoto H, Ihara Y, 
Takashima A. Toxic tau oligomer formation blocked by capping of cysteine residues 
with 1,2-dihydroxybenzene groups. Nature Communications. 2015;16(6):10216. DOI: 10. 
1038/ncomms10216
[38] Alejandra del CA, Tanweer Z, Michal N, Inge GI, Khalid I. Hyperphosphorylation 
induces self-assembly of τ into tangles of paired helical filaments/straight filaments. 
Proceedings of the National Academy of Sciences of the United States of America. 
2001;98(12):6923-6928. DOI: 10.1073/pnas.121119298
[39] Sahara N, Maeda S, Takashima A. Tau oligomerization: A role for tau aggregation inter-
mediates linked to neurodegeneration. Current Alzheimer Research. 2008;5(6):591-598. 
DOI: 10.2174/156720508786898442
[40] Sahara N, Maeda S, Murayama M, Suzuki T, Dohmae N, Yen SH, Takashima A. Assembly 
of two distinct dimers and higher-order oligomers from full-length tau. The European 
Journal of Neuroscience. 2007;25(10):3020-3029. DOI: 10.1111/j.1460-9568.2007.05555.x
[41] Alavi Naini SM, Soussi-Yanicostas N. Tau hyperphosphorylation and oxidative stress, 
a critical vicious circle in neurodegenerative Tauopathies? Oxidative Medicine and 
Cellular Longevity. 2015;2015:151979. DOI: 10.1155/2015/151979
[42] AuthAl-Hilaly YK, Pollack SJ, Vadukul D, Citossi F, Rickard JE, Simpson M, Storey JMD, 
Harrington CR, Wischik CM, Serpell LC. Alzheimer's disease-like paired helical filament 
assembly from truncated tau protein is independent of disulphide cross-linking. Journal 
of Molecular Biology. Forthcoming. DOI: 10.1016/j.jmb.2017.09.007
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
51
[43] Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, 
McBride JD, Trojanowski JQ, Lee VM. Unique pathological tau conformers from 
Alzheimer's brains transmit tau pathology in nontransgenic mice. The Journal of 
Experimental Medicine. 2016;213(12):2635-2654. DOI: 10.1084/jem.20160833
[44] Maeda S, Sahara N, Saito Y, Murayama M, Yoshilke Y, Kim H, Miyasaka T, Murayama S, 
Ikai A, Takashima A. Granular tau oligomers as intermediates of tau filaments. Bio-
chemistry. 2007;46(12):3856-3861. DOI: 10.1021/bi061359o
[45] Šimić G, Leko MB, Jovanov-Milošević N, Wray S, de Silva R, Harrington C, Wischik C, 
Delalle I, Bažadona D, Buée L, Di Giovanni G, Hof PR. Tau protein hyperphosphoryla-
tion and aggregation in Alzheimer’s disease and other Tauopathies, and possible neuro-
protective strategies. Biomolecules 2016;6(1):1-28. DOI: 10.3390/biom6010006
[46] Murray ME, Kouri N, Lin WL, Jack CR Jr, Dickson DW, Vemuri P. Clinicopathologic 
assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer's 
Research & Therapy. 2014;6(1):1. DOI: 10.1186/alzrt231
[47] Kahlson MA, Colodner KJ. Glial tau pathology in Tauopathies: Functional conse-
quences. Journal of Experimental Neuroscience. 2016;9(Suppl 2):43-50. DOI: 10.4137/JEN. 
S25515
[48] Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, 
Ghetti B, Goedert M, Scheres SHW. Cryo-EM structures of tau filaments from Alzheimer's 
disease. Nature. 2017;547(7662):185-190. DOI: 10.1038/nature23002
[49] Drubin D, Kobayashi S, Kellogg D, Kirschner M. Regulation of microtubule protein lev-
els during cellular morphogenesis in nerve growth factor-treated PC12 cells. The Journal 
of Cell Biology. 1988;106(5):1583-1591
[50] David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal deg-
radation of tau protein. Journal of Neurochemistry. 2002;83(1):176-185. DOI: 10.1046/j. 
1471-4159.2002.01137.x
[51] Chesser AS, Pritchard SM, Johnson GV. Tau clearance mechanisms and their possible 
role in the pathogenesis of Alzheimer disease. Frontiers in Neurology. 2013;4:122. DOI: 
10.3389/fneur.2013.00122
[52] Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, Davies KJ, Grune T. 
Phosphorylation inhibits turnover of the tau protein by the proteasome: Influence of 
RCAN1 and oxidative stress. The Biochemical Journal. 2016;400(3):511-520. DOI: 10.1042/ 
BJ20060463
[53] Guo JL, Buist A, Soares A, Callaerts K, Calafate S, Stevenaert F, Daniels JP, Zoll BE, 
Crowe A, Brunden KR, Moechars D, Lee VM. The dynamics and turnover of tau aggre-
gates in cultured cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES. The Journal 
of Biological Chemistry. 2016;291(25):13175-13193. DOI: 10.1074/jbc.M115.712083
[54] Piras A, Collin L, Grüninger F, Graff C, Rönnbäck A. Autophagic and lysosomal defects 
in human tauopathies: Analysis of post-mortem brain from patients with familial 
Cognitive Disorders52
Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Acta 
Neuropathologica Communications. 2016;4:22. DOI: 10.1186/s40478-016-0292-9
[55] Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease--locating the primary 
defect. Neurobiology of Disease. 2011;43(1):38-45. DOI: 10.1016/j.nbd.2011.01.021
[56] Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, 
Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA. Lysosomal 
proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related 
PS1 mutations. Cell. 2010;141(7):1146-1158. DOI: 10.1016/j.cell.2010.05.008
[57] Myeku N, Clelland CL, Emrani S, Kukushkin NV, WH Y, Goldberg AL, Duff KE. Tau-
driven 26S proteasome impairment and cognitive dysfunction can be prevented early 
in disease by activating cAMP-PKA signaling. Nature Medicine. 2016;22(1):46-53. DOI: 
10.1038/nm.4011
[58] Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical fila-
ment-tau in brains of patients with Alzheimer's disease. Journal of Neurochemistry. 
2003;85(1):115-122. DOI: 10.1046/j.1471-4159.2003.01642.x
[59] Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, Ichikawa M, Yamaguchi H, 
Takashima A. Neurodegeneration with tau accumulation in a transgenic mouse express-
ing V337M human tau. The Journal of Neuroscience. 2002;22(1):133-141
[60] Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific 
conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated 
through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. The Journal of Biological 
Chemistry. 2006;281(16):10825-10838. DOI: 10.1074/jbc.M512786200
[61] Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: The ubiquitin-proteasome system 
versus the autophagy-lysosome system. Progress in Neurobiology. 2013;105:49-59. DOI: 
10.1016/j.pneurobio.2013.03.001
[62] Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: The interplay 
of autophagy and apoptosis. Nature Reviews. Molecular Cell Biology. 2014;15(2):81-94. 
DOI: 10.1038/nrm3735
[63] Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682. 
DOI: 10.1016/S0140-6736(15)00461-4
[64] Takada LT. The genetics of monogenic Frontotemporal dementia. Dementia e Neuro-
psychologia. 2015;9(3):219-229. DOI: 10.1590/1980-57642015DN93000003
[65] Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, 
Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, 
Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, 
Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, 
Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, 
Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, 
Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of  missense 
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
53
and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 
393(6686):702-705. DOI: 10.1038/31508
[66] Goedert M. Tau gene mutations and their effects. Movement Disorders. 2005;(Suppl 12): 
S45-S52. DOI: 10.1002/mds.20539
[67] Alzforum. Mutations [Internet]. 2015.05.29 . Available from: http://www.alzforum.org/
mutations [Accessed: 2017.10.07]
[68] Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, 
Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, 
Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, 
Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, 
Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, 
Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, 
Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, 
Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, 
Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, 
Pericak-Vance MA, Farrer LA, Ross OA, Rademakers R, Schellenberg GD, Miller BL, 
Mandelkow E, Geschwind DH. Evidence for a role of the rare p.A152T variant in MAPT 
in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular 
Genetics. 2012;21(15):3500-3512. DOI: 10.1093/hmg/dds161
[69] Wolfe MS. Tau mutations in neurodegenerative diseases. The Journal of Biological 
Chemistry. 2009;284(10):6021-6025. DOI: 10.1074/jbc.R800013200
[70] Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, 
Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. 
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice express-
ing human P301S tau protein. The Journal of Neuroscience. 2002;22(21):9340-9351. DOI: 
10.4172/2161-0460.1000327
[71] Gistelinck M, Lambert JC, Callaerts P, Dermaut B, Dourlen P. Drosophila models of 
Tauopathies: What have we learned? International Journal of Alzheimer's Disease. 2012; 
2012:970980. DOI: 10.1155/2012/970980
[72] Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, Fälting J, Distel M, 
Köster RW, Schmid B, Haass C. A zebrafish model of tauopathy allows in vivo imag-
ing of neuronal cell death and drug evaluation. The Journal of Clinical Investigation. 
2009;119(5):1382-1395. DOI: 10.1172/JCI37537
[73] Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. 
Nature Reviews. Neuroscience. 2008;9(7):532-544. DOI: 10.1038/nrn2420
[74] TH W, YN L, Chuang CL, CL W, Chiang AS, Krantz DE, Chang HY. Loss of vesicu-
lar dopamine release precedes tauopathy in degenerative dopaminergic neurons in a 
Drosophila model expressing human tau. Acta Neuropathologica. 2013;125(5):711-725. 
DOI: 10.1007/s00401-013-1105-x
Cognitive Disorders54
[75] Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, GJ X, Dombroski BA, Jeong D, 
Dichter MA, Juul H, Loomis E, Raskind M, Leverenz JB, Trojanowski JQ, Lee VM, 
Schellenberg GD, Kraemer BC. High copy wildtype human 1N4R tau expression pro-
motes early pathological tauopathy accompanied by cognitive deficits without progres-
sive neurofibrillary degeneration. Acta Neuropathologica Communications. 2015;3:33. 
DOI: 10.1186/s40478-015-0210-6
[76] Bondulich MK, Guo T, Meehan C, Manion J, Rodriguez Martin T, Mitchell JC, Hortobagyi T, 
Yankova N, Stygelbout V, Brion JP, Noble W, Hanger DP. Tauopathy induced by low 
level expression of a human brain-derived tau fragment in mice is rescued by phen-
ylbutyrate. Tauopathy induced by low level expression of a human brain-derived tau 
fragment in mice is rescued by phenylbutyrate. Brain. 2016;139(Pt 8):2290-2306. DOI: 
10.1093/brain/aww137
[77] Götz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM. A 
decade of tau transgenic animal models and beyond. Brain Pathology. 2007;17(1):91-103. 
DOI: 10.1111/j.1750-3639.2007.00051.x
[78] Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, 
Van Leuven F. Changed conformation of mutant tau-P301L underlies the moribund 
tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice. 
The Journal of Biological Chemistry. 2005;280(5):3963-3973. DOI: 10.1074/jbc.M409876200
[79] Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, 
Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a 
P301S tauopathy mouse model. Neuron. 2007;53(3):337-351. DOI: 10.1016/j.neuron.2007. 
01.010
[80] Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, 
Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, 
Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model 
improves memory function. Science. 2005;309(5733):476-481. DOI: 10.1126/science. 
1113694
[81] Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, 
Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, 
Ebneth A, Hardy J, Leroy K, Brion JP, Vanderhaeghen P, De Strooper B. Hallmarks of 
Alzheimer's disease in stem-cell-derived human neurons transplanted into mouse brain. 
Neuron. 2017;93(5):1066-1081. DOI: 10.1016/j.neuron.2017.02.001
[82] Kontaxi C, Piccardo P, Gill AC. Lysine-directed post-translational modifications of tau 
protein in Alzheimer's disease and related Tauopathies. Frontiers in Molecular Bio-
sciences. 2017;4:56. DOI: 10.3389/fmolb.2017.00056
[83] Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L. 
Tau post-translational modifications in wild-type and human amyloid precursor protein 
transgenic mice. Nature Neuroscience. 2015;18(8):1183-1189. DOI: 10.1038/nn.4067
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
55
[84] Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau 
protein kinases: involvement in Alzheimer's disease. Ageing Research Reviews. 2013; 
12(1):289-309. DOI: 10.1016/j.arr.2012.06.003
[85] Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MW, Al-Ramahi I, Jafar-Nejad P, 
Vilanova-Velez L, See L, De Maio A, Nitschke L, Wu Z, Troncoso JC, Westbrook TF, 
Tang J, Botas J, Zoghbi HY. Reduction of Nuak1 decreases tau and reverses pheno-
types in a Tauopathy mouse model. Neuron 2016;92(2):407-418. DOI: 10.1016/j.neuron. 
2016.09.022
[86] Credle JJ, George JL, Wills J, Duka V, Shah K, Lee YC, Rodriguez O, Simkins T, Winter M, 
Moechars D, Steckler T, Goudreau J, Finkelstein DI, Sidhu A. GSK-3β dysregulation 
contributes to parkinson's-like pathophysiology with associated region-specific phos-
phorylation and accumulation of tau and α-synuclein. Cell Death and Differentiation. 
2015;22(5):838-851. DOI: 10.1038/cdd.2014.179
[87] Yang W, Leystra-Lantz C, Strong MJ. Upregulation of GSK3beta expression in fron-
tal and temporal cortex in ALS with cognitive impairment. Brain Research. 2008;1196: 
131-139. DOI: 10.1016/j.brainres
[88] Gratuze M, Noël A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, Dickler M, Goupil C, 
Bezeau F, Poitras I, Bissonnette S, Whittington RA, Hébert SS, Cicchetti F, Parker JA, 
Samadi P, Planel E. Tau hyperphosphorylation and deregulation of calcineurin in mouse 
models of Huntington's disease. Human Molecular Genetics. 2015;24(1):86-99. DOI: 
10.1093/hmg/ddu456
[89] Yang WJ, Chen W, Chen L, Guo YJ, Zeng JS, Li GY, Tong WS. Involvement of tau 
phosphorylation in traumatic brain injury patients. Acta Neurologica Scandinavica. 
2017;135(6):622-627. DOI: 10.1111/ane.12644
[90] Dey A, Hao S, Wosiski-Kuhn M, Stranahan AM. Glucocorticoid-mediated activa-
tion of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes. 
Neurobiology of Aging. 2017;57:75-83. DOI: 10.1016/j.neurobiolaging
[91] Hashiguchi M, Hashiguchi T. Kinase-kinase interaction and modulation of tau phos-
phorylation. In: Jeon KW, editor. International Review of Cell and Molecular Biology. 1st 
ed. Academic Press: Elsevier; 2013. pp. 121-160. DOI: 10.1016/B978-0-12-405210-9.00004-7
[92] Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. 
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: In vitro evidence 
and implications for tangle formation in vivo. Journal of Neurochemistry. 2006;97(4): 
1005-1014. DOI: 10.1111/j.1471-4159.2006.03784.x
[93] Alzhforum. Antibodies [Internet]. 2014.05.20 . Available from: http://www.alzforum.org/ 
antibodies/search?category[616]=Tau [Accessed: 2017.10.13]
[94] Prokopovich DV, Whittaker JW, Muthee MM, Ahmed A, L1 L. Impact of phosphoryla-
tion and Pseudophosphorylation on the early stages of aggregation of the microtubule-
associated protein tau. The Journal of Physical Chemistry. B. 2017;121(9):2095-2103. DOI: 
10.1021/acs.jpcb.7b00194
Cognitive Disorders56
[95] Chang E, Kim S, Schafer KN, Kuret J. Pseudophosphorylation of tau protein directly 
modulates its aggregation kinetics. Biochimica et Biophysica Acta. 2011;1814(2):388-
395. DOI: 10.1016/j.bbapap.2010.10.005
[96] Llorens-Martín M, Jurado J, Hernández F, Avila J. GSK-3β, a pivotal kinase in Alzheimer 
disease. Frontiers in Molecular Neuroscience. 2014;7:46. DOI: 10.3389/fnmol.2014.00046
[97] Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. Journal 
of Neurochemistry. 2008;104(6):1433-1439. DOI: 10.1111/j.1471-4159.2007.05194.x
[98] Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK. 
Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. The 
Journal of Biological Chemistry. 2002;277(14):11933-11940. DOI: 10.1074/jbc.M107182200
[99] Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease 
and accumulation in argyrophilic grains and in neurones at different stages of neuro-
fibrillary degeneration.. Neuropathology and Applied Neurobiology 2007;33(1):43-55. 
DOI: 10.1111/j.1365-2990.2006.00795.x
[100] Rankin CA, Sun Q, Gamblin TC. Pre-assembled tau filaments phosphorylated by 
GSK-3b form large tangle-like structures. Neurobiology of Disease. 2008;31(3):368-377. 
DOI: 10.1016/j.nbd.2008.05.011
[101] Crespo-Biel N, Theunis C, Borghgraef P, Lechat B, Devijver H, Maurin H, Van 
Leuven F. Phosphorylation of protein tau by GSK3β prolongs survival of bigenic 
tau.P301L×GSK3β mice by delaying brainstem tauopathy. Neurobiology of Disease. 
2014;67:119-132. DOI: 10.1016/j.nbd.2014.03.016
[102] Li B, Ryder J, Su Y, Moore SA, Liu F, Solenberg P, Kellie B, Fox N, Ni BH, Liu RG, 
Zhou Y. Overexpression of GSK3βS9A resulted in tau hyperphosphorylation and mor-
phology reminiscent of pretangle-like neurons in the brain of PDGSK3β transgenic mice. 
Transgenic Research. 2004;13(4):385-396. DOI: 10.1023/B:TRAG.0000040039.44899.6f
[103] Gómez de Barreda E, Pérez M, Gómez Ramos P, de Cristobal J, Martín-Maestro P, Morán A, 
Dawson HN, Vitek MP, Lucas JJ, Hernández F, Avila J. Tau-knockout mice show 
reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiology 
of Disease 2010;37(3):622-629. DOI: 10.1016/j.nbd.2009.11.017
[104] Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glyco-
gen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. The 
Biochemical Journal. 2004;377(Pt 1):249-255. DOI: 10.1042/BJ20031259
[105] Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and 
diseases. Pharmacology & Therapeutics. 2015;148:114-131. DOI: 10.1016/j.pharmthera
[106] Vallée A, Lecarpentier Y. Alzheimer disease: Crosstalk between the canonical Wnt/
Beta-catenin pathway and PPARs alpha and gamma. Frontiers in Neuroscience. 2016; 
19(10):459. DOI: 10.3389/fnins.2016.00459
[107] Medina M, Garrido JJ, Wandosell FG. Modulation of GSK-3 as a therapeutic strategy 
on tau pathologies. Frontiers in Molecular Neuroscience. 2011;4:24. DOI: 10.3389/fnmol. 
2011.00024
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
57
[108] Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. PHF-tau from Alzheimer's 
brain comprises four species on SDS-PAGE which can be mimicked by in vitro phos-
phorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Letters. 1994; 
349(3):359-364
[109] Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX. Site-specific effects of tau phos-
phorylation on its microtubule assembly activity and self-aggregation. The European 
Journal of Neuroscience. 2007;26(12):3429-3436. DOI: 10.1111/j.1460-9568.2007.05955.x
[110] Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau 
phosphorylation at Ser396 in Alzheimer's disease recapitulates development and con-
tributes to reduced microtubule binding. Neuron. 1993;10(6):1089-1099
[111] Regan P, Piers T, Yi JH, Kim DH, Huh S, Park SJ, Ryu JH, Whitcomb DJ, Cho K. Tau 
phosphorylation at serine 396 residue is required for hippocampal LTD. The Journal of 
Neuroscience. 2015;35(12):4804-4812. DOI: 10.1523/JNEUROSCI.2842-14.2015
[112] Li G, Yin H, Kuret J. Casein kinase 1 delta phosphorylates tau and disrupts its binding 
to microtubules. The Journal of Biological Chemistry. 2004;279(16):15938-15945. DOI: 
10.1074/jbc.M314116200
[113] Ghosh A, Giese KP. Calcium/calmodulin-dependent kinase II and Alzheimer's disease. 
Molecular Brain. 2015;8(1):78. DOI: 10.1186/s13041-015-0166-2
[114] Ploia C, Antoniou X, Sclip A, Grande V, Cardinetti D, Colombo A, Canu N, Benussi L, 
Ghidoni R, Forloni G, Borsello T. JNK plays a key role in tau hyperphosphorylation in 
Alzheimer's disease models. Journal of Alzheimer's Disease. 2011;26(2):315-329. DOI: 
10.3233/JAD-2011-110320
[115] Noël A, Poitras I, Julien J, Petry FR, Morin F, Charron J, Planel E. ERK (MAPK) does not 
phosphorylate tau under physiological conditions in vivo or in vitro. Neurobiology of 
Aging. 2015;36(2):901-902. DOI: 10.1016/j.neurobiolaging.2014.11.005
[116] Luna-Muñoz J, Chávez-Macías L, García-Sierra F, Mena R. Earliest stages of tau con-
formational changes are related to the appearance of a sequence of specific phospho- 
dependent tau epitopes in Alzheimer's disease. Journal of Alzheimer's Disease. 2007; 
12(4):365-375. DOI: 10.3233/JAD-2007-12410
[117] Laske C, Stellos K, Kempter I, Stransky E, Maetzler W, Fleming I, Randriamboavonjy V. 
Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's 
disease. Alzheimer's & Dementia. 2015;11(5):465-474. DOI: 10.1016/j.jalz.2014.06.003
[118] Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn 
TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle 
pathology. The Journal of Clinical Investigation. 2004;114(1):121-130. DOI: 10.1172/
JCI20640
[119] Chu J, Lauretti E, Praticò D. Caspase-3-dependent cleavage of Akt modulates tau 
phosphorylation via GSK3β kinase: Implications for Alzheimer's disease. Molecular 
Psychiatry. 2017;22(7):1002-1008. DOI: 10.1038/mp.2016.214
Cognitive Disorders58
[120] Ferreira A. Calpain Dysregulation in Alzheimer’s disease. ISRN Biochemistry. 2012; 
2012:728571. DOI: 10.5402/2012/728571
[121] Jin N, Yin X, Yu D, Cao M, Gong CX, Iqbal K, Ding F, Gu X, Liu F. Truncation and acti-
vation of GSK-3β by calpain I: A molecular mechanism links to tau hyperphosphoryla-
tion in Alzheimer's disease. Scientific Reports. 2015;5:8187. DOI: 10.1038/srep08187
[122] García-Sierra F, Mondragón-Rodríguez S, Basurto-Islas G. Truncation of tau protein 
and its pathological significance in Alzheimer's disease. Journal of Alzheimer's Disease. 
2008;14(4):401-409. DOI: 10.3233/JAD-2008-14407
[123] Basurto-Islas G, Luna-Muñoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, García-Sierra F. 
Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary 
tangles correlates with progression in Alzheimer disease. Journal of Neuropathology 
and Experimental Neurology. 2008;67(5):470-483. DOI: 10.1097/NEN.0b013e31817275c7
[124] AuthMeduri G, Guillemeau K, Dounane O, Sazdovitch V, Duyckaerts C, Chambraud B, 
Baulieu EE, Giustiniani J. Caspase-cleaved tau-D(421) is colocalized with the immu-
nophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer's disease neu-
rons. Neurobiology of Aging. 2016;46:124-137. DOI: 10.1016/j.neurobiolaging.2016.06.017
[125] Means JC, Gerdes BC, Kaja S, Sumien N, Payne AJ, Stark DA, Borden PK, Price JL, 
Koulen P. Caspase-3-dependent Proteolytic cleavage of tau causes neurofibrillary tan-
gles and results in cognitive impairment during normal aging. Neurochemical Research. 
2016;41(9):2278-2288. DOI: 10.1007/s11064-016-1942-9
[126] Zhao H, Zhao W, Lok K, Wang Z, Yin M. A synergic role of caspase-6 and caspase-3 in 
tau truncation at D421 induced by H2O2. Cellular and Molecular Neurobiology. 2014; 
34(3):369-378. DOI: 10.1007/s10571-013-0021-x
[127] Wang Y, Garg S, Mandelkow EM, Mandelkow E. Proteolytic processing of tau. Bio-
chemical Society Transactions. 2010;38(4):955-961. DOI: 10.1042/BST0380955
[128] Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease 
resistant tau unit of the Alzheimer's disease paired helical filament. The EMBO Journal. 
1993;12(1):365-370
[129] de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. 
Caspase activation precedes and leads to tangles. Nature. 2010;464(7292):1201-1204. 
DOI: 10.1038/nature08890
[130] Kurbatskaya K, Phillips EC, Croft CL, Dentoni G, Hughes MM, Wade MA, Al-Sarraj S, 
Troakes C, O'Neill MJ, Perez-Nievas BG, Hanger DP, Noble W. Upregulation of cal-
pain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's 
disease brain. Acta Neuropathologica Communications. 2016;4:34. DOI: 10.1186/
s40478-016-0299-2
[131] Jin N, Wu Y, Xu W, Gong CX, Iqbal K, Liu F. C-terminal truncation of GSK-3β 
enhances its dephosphorylation by PP2A. FEBS Letters. 2017;591(7):1053-1063. DOI: 
10.1002/1873-3468.12617
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
59
[132] Matsumoto SE, Motoi Y, Ishiguro K, Tabira T, Kametani F, Hasegawa M, Hattori N. The 
twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: 
Implications of prion-like properties. Human Molecular Genetics. 2015;24(22):6403-6416. 
DOI: 10.1093/hmg/ddv351
[133] Kim Y, Choi H, Lee W, Park H, Kam TI, Hong SH, Nah J, Jung S, Shin B, Lee H, 
Choi TY, Choo H, Kim KK, Choi SY, Kayed R, Jung YK. Caspase-cleaved tau exhibits 
rapid memory impairment associated with tau oligomers in a transgenic mouse model. 
Neurobiology of Disease. 2016;87:19-28. DOI: 10.1016/j.nbd.2015.12.006
[134] Mead E, Kestoras D, Gibson Y, Hamilton L, Goodson R, Jones S, Eversden S, Davies P, 
O'Neill M, Hutton M, Szekeres P, J1 W. Halting of Caspase activity protects tau from 
MC1-conformational change and aggregation. Journal of Alzheimer's Disease. 2016; 
54(4):1521-1538. DOI: 10.3233/JAD-150960
[135] Sandhu P, Naeem MM, Lu C, Kumarathasan P, Gomes J, Basak A. Ser422 phosphoryla-
tion blocks human tau cleavage by caspase-3: Biochemical implications to Alzheimer's 
disease. Bioorganic & Medicinal Chemistry Letters. 2017;27(3):642-652. DOI: 10.1016/j.
bmcl.2016.11.087
[136] Sato S, Cerny RL, Buescher JL, Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific 
tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of 
Neurochemistry. 2006;98(5):1573-1584. DOI: 10.1111/j.1471-4159.2006.04059.x
[137] Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, Cleary J, Ashe KH. 
Caspase-2 cleavage of tau reversibly impairs memory. Nature Medicine. 2016;22(11): 
1268-1276. DOI: 10.1038/nm.4199
[138] Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, 
Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its 
degradation and contributes to tauopathy. Neuron. 2010;67(6):953-966. DOI: 10.1016/j.
neuron.2010.08.044
[139] Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM. The acet-
ylation of tau inhibits its function and promotes pathological tau aggregation. Nature 
Communications. 2011;2:252. DOI: 10.1038/ncomms1255
[140] Gorsky MK, Burnouf S, Sofola-Adesakin O, Dols J, Augustin H, Weigelt CM, Grönke S. 
Partridge . Pseudo-acetylation of multiple sites on human tau proteins alters tau phos-
phorylation and microtubule binding, and ameliorates amyloid beta toxicity. Scientific 
Reports. 2017;7(1):9984. DOI: 10.1038/s41598-017-10225-0
[141] Trzeciakiewicz H, Tseng JH, Wander CM, Madden V, Tripathy A, Yuan CX, Cohen TJ. A 
Dual pathogenic mechanism links tau acetylation to sporadic Tauopathy. Scientific 
Reports. 2017;13(7):44102. DOI: 10.1038/srep44102
[142] Gorsky MK, Burnouf S, Dols J, Mandelkow E, Partridge L. Acetylation mimic of lysine 
280 exacerbates human tau neurotoxicity in vivo. Scientific Reports. 2016;6:22685. DOI: 
10.1038/srep22685
Cognitive Disorders60
[143] Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, 
Mok SA5, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, 
Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L. Critical role of acetylation in 
tau-mediated neurodegeneration and cognitive deficits. Nature Medicine. 2015;21(10): 
1154-1162. DOI: 10.1038/nm.3951
[144] Carlomagno Y, Chung DC, Yue M, Castanedes-Casey M, Madden BJ, Dunmore J, Tong J, 
DeTure M, Dickson DW, Petrucelli L, Cook C. An acetylation-phosphorylation switch 
that regulates tau aggregation propensity and function. The Journal of Biological 
Chemistry. 2017;292(37):15277-15286. DOI: 10.1074/jbc.M117.794602
[145] Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer 
disease. The FEBS Journal. 2014;281(1):46-62. DOI: 10.1111/febs.12590
[146] Frenkel-Pinter M, Stempler S, Tal-Mazaki S, Losev Y, Singh-Anand A, Escobar-
Álvarez D, Lezmy J, Gazit E, Ruppin E, Segal D. Altered protein glycosylation pre-
dicts Alzheimer's disease and modulates its pathology in disease model Drosophila. 
Neurobiology of Aging. 2017;56:159-171. DOI: 10.1016/j.neurobiolaging.2017.04.020
[147] Khanna MR, Kovalevich J, Lee VM, Trojanowski JQ, Brunden KR. Therapeutic strate-
gies for the treatment of tauopathies: Hopes and challenges. Alzheimer's & Dementia. 
2016;12(10):1051-1065. DOI: 10.1016/j.jalz.2016.06.006
[148] Alzforum. Therapeutics [Internet]. Available from: http://www.alzforum.org/therapeu-
tics/rember-tm [Accessed: 2017.10.14]
[149] Martin M. Targeting Tau Degradation by Small Molecule Inhibitors for Treatment of 
Tauopathies [thesis]. Graduate Theses and Dissertations.: University of South Florida; 
2016. 121 p. Available from: http://scholarcommons.usf.edu/etd/6314
[150] Cao Y, Jia XX, Wei Y, Liu MX, Liu JG, Li H. Traditional Chinese medicine Huannao Yicong 
decoction extract decreases tau hyperphosphorylation in the brain of Alzheimer's dis-
ease model rats induced by Aβ 1-42. Evidence-based Complementary and Alternative 
Medicine. 2016;2016:6840432. DOI: 10.1155/2016/6840432
[151] Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation 
inhibitors for Alzheimer disease. Journal of Medicinal Chemistry. 2013;56(11):4135-4155. 
DOI: 10.1021/jm3017317
[152] Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of 
Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National 
Academy of Sciences of the United States of America. 1996;93(20):11213-11218
[153] Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, 
Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, 
Wischik CM. Cellular models of aggregation-dependent template-directed  proteolysis 
to characterize tau aggregation inhibitors for treatment of Alzheimer disease. The Journal 
of Biological Chemistry. 2015;290(17):10862-10875. DOI: 10.1074/jbc.M114.616029
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
61
[154] Rickard JE, Horsley D, Wischik CM, Harrington CR. Assays for the screening and char-
acterization of tau aggregation inhibitors. Methods in Molecular Biology. 2017;1523: 
129-140. DOI: 10.1007/978-1-4939-6598-4_8
[155] Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, 
Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, 
Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. Efficacy and safety 
of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's 
disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 
2016;388(10062):2873-2884. DOI: 10.1016/S0140-6736(16)31275-2
[156] Cisek K, Cooper GL, Huseby CJ, Kuret J. Structure and mechanism of action of tau 
aggregation inhibitors. Current Alzheimer Research. 2014;11(10):918-927. DOI: 10.1021/
jm3017317
[157] Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends in 
Molecular Medicine. 2015;21(6):394-402. DOI: 10.1016/j.molmed.2015.03.003
[158] Sigurdsson EM. Tau immunotherapy. Neurodegenerative Diseases. 2016;16(1-2):34-38. 
DOI: 10.1159/000440842
[159] Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting 
pathological tau conformers in a tangle mouse model reduces brain pathology with 
associated functional improvements. The Journal of Neuroscience. 2007;27(34):9115-
9229. DOI: 10.1523/JNEUROSCI.2361-07.2007
[160] Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard 
P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurode-
generative phenotype in tauopathies. Proceedings of the National Academy of Sciences 
of the United States of America. 2007;104(22):9511-9516. DOI: 10.1073/pnas.0701055104
[161] Dou F, Chang XY, Ma D. Hsp90 maintains the stability and function of the tau phos-
phorylating kinase GSK3β. International Journal of Molecular Sciences. 2007;8(1):51-60
[162] Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting Hsp90/Hsp70-based protein 
quality control for treatment of adult onset neurodegenerative diseases. Annual Review 
of Pharmacology and Toxicology. 2015;55:353-371. DOI: 10.1146/annurev-pharmtox- 
010814-124332
[163] Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, 
Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, 
Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP and Hsp70 regulate tau ubiquiti-
nation, degradation and aggregation. Human Molecular Genetics. 2004;13(7):703-714. 
DOI: 10.1093/hmg/ddh083
[164] Shelton LB, Baker JD, Zheng D, Sullivan LE, Solanki PK, Webster JM, Sun Z, Sabbagh JJ, 
Nordhues BA, Koren J, Ghosh S, Blagg BSJ, Blair LJ, Dickey CA. Hsp90 activator 
Aha1 drives production of pathological tau aggregates. Proceedings of the National 
Academy of Sciences of the United States of America. 2017;114(36):9707-9712. DOI: 
10.1073/pnas.1707039114
Cognitive Disorders62
[165] Yeh CH, Huang HC, Chang KS, Yang ML, Tsai SL, Lin HW, Kuan YH. Yi-chi-Tsung-Ming-
tang reduced a beta(1-40)-induced neurotoxicity via of acetylcholine and NMDA receptors 
expression, ROS generation and tau phosphorylation. Indian Journal of Pharmaceutical 
Sciences. 2017;79(3):411-419. DOI: 10.4172/pharmaceutical-sciences.1000244
[166] Sulistio YA, Heese K. Proteomics in traditional Chinese medicine with an emphasis 
on Alzheimer's disease. Evidence-based Complementary and Alternative Medicine. 
2015;2015:393510. DOI: 10.1155/2015/393510
[167] Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, 
Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, 
Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, 
Cruchaga C, Alzheimer’s Disease Neuroimaging Initiative, Fagan AM, Miller BL, Boxer AL, 
Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM. ApoE4 markedly exacer-
bates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017; 
549(7673):523-527. DOI: 10.1038/nature24016
[168] Giehl K, Reetz K, Dogan I, Werner C, Schulz JB, Hammes J, Drzezga A, van Eimeren T. 
Tau pathology in Huntington's disease: A brief in vivo PET-imaging report. Basal 
Ganglia 2017;8:13. DOI: 10.1016/j.baga.2017.02.038
Tauopathy
http://dx.doi.org/10.5772/intechopen.73198
63

